Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

Journal of Pharmacy Practice (JPP)Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels with Respect to Known Doses in Relation to Major Bleeding Events

Anti-Xa levels could be helpful for determining current medication concentrations, determining the immediate safety of therapy, and providing direction for potential clinical actions. Further study is needed to determine how dose titration and reversal therapy based on anti-Xa level results in significant bleeding.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
OBR Oncology
Oncology Learning Network
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form